These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 23999693)

  • 1. Exposure-response analysis of pertuzumab in HER2-positive metastatic breast cancer: absence of effect on QTc prolongation and other ECG parameters.
    Garg A; Li J; Clark E; Knott A; Carrothers TJ; Marier JF; Cortés J; Brewster M; Visich J; Lum B
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1133-41. PubMed ID: 23999693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pertuzumab: a review of its use for first-line combination treatment of HER2-positive metastatic breast cancer.
    McCormack PL
    Drugs; 2013 Sep; 73(13):1491-502. PubMed ID: 23982598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel.
    Cortés J; Swain SM; Kudaba I; Hauschild M; Patel T; Grincuka E; Masuda N; McNally V; Ross G; Brewster M; Marier JF; Trinh MM; Garg A; Nijem I; Visich J; Lum BL; Baselga J
    Anticancer Drugs; 2013 Nov; 24(10):1084-92. PubMed ID: 23969513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trastuzumab, in combination with carboplatin and docetaxel, does not prolong the QT interval of patients with HER2-positive metastatic or locally advanced inoperable solid tumors: results from a phase Ib study.
    Xu N; Redfern CH; Gordon M; Eppler S; Lum BL; Trudeau C
    Cancer Chemother Pharmacol; 2014 Dec; 74(6):1251-60. PubMed ID: 25344761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
    Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
    Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Onartuzumab with or without bevacizumab in combination with weekly paclitaxel does not prolong QTc or adversely affect other ECG parameters in patients with locally recurrent or metastatic triple-negative breast cancer.
    Borin MT; Chen M; Mocci S; Rubets I; Chittenden J; Aldairy W; Stroh M
    Cancer Chemother Pharmacol; 2015 Feb; 75(2):401-10. PubMed ID: 25542267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.
    Baselga J; Cortés J; Kim SB; Im SA; Hegg R; Im YH; Roman L; Pedrini JL; Pienkowski T; Knott A; Clark E; Benyunes MC; Ross G; Swain SM;
    N Engl J Med; 2012 Jan; 366(2):109-19. PubMed ID: 22149875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study.
    Swain SM; Ewer MS; Cortés J; Amadori D; Miles D; Knott A; Clark E; Benyunes MC; Ross G; Baselga J
    Oncologist; 2013; 18(3):257-64. PubMed ID: 23475636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer.
    Cortés J; Baselga J; Im YH; Im SA; Pivot X; Ross G; Clark E; Knott A; Swain SM
    Ann Oncol; 2013 Oct; 24(10):2630-2635. PubMed ID: 23868905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pertuzumab (Perjeta®) approval in HER2-positive metastatic breast cancers].
    Sabatier R; Gonçalves A
    Bull Cancer; 2014; 101(7-8):765-71. PubMed ID: 25091659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.
    Swain SM; Miles D; Kim SB; Im YH; Im SA; Semiglazov V; Ciruelos E; Schneeweiss A; Loi S; Monturus E; Clark E; Knott A; Restuccia E; Benyunes MC; Cortés J;
    Lancet Oncol; 2020 Apr; 21(4):519-530. PubMed ID: 32171426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.
    Swain SM; Kim SB; Cortés J; Ro J; Semiglazov V; Campone M; Ciruelos E; Ferrero JM; Schneeweiss A; Knott A; Clark E; Ross G; Benyunes MC; Baselga J
    Lancet Oncol; 2013 May; 14(6):461-71. PubMed ID: 23602601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
    Gianni L; Pienkowski T; Im YH; Roman L; Tseng LM; Liu MC; Lluch A; Staroslawska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi G; Szado T; Ratnayake J; Ross G; Valagussa P
    Lancet Oncol; 2012 Jan; 13(1):25-32. PubMed ID: 22153890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.
    Swain SM; Baselga J; Kim SB; Ro J; Semiglazov V; Campone M; Ciruelos E; Ferrero JM; Schneeweiss A; Heeson S; Clark E; Ross G; Benyunes MC; Cortés J;
    N Engl J Med; 2015 Feb; 372(8):724-34. PubMed ID: 25693012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer.
    Bianchini G; Kiermaier A; Bianchi GV; Im YH; Pienkowski T; Liu MC; Tseng LM; Dowsett M; Zabaglo L; Kirk S; Szado T; Eng-Wong J; Amler LC; Valagussa P; Gianni L
    Breast Cancer Res; 2017 Feb; 19(1):16. PubMed ID: 28183321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.
    Martin M; Fumoleau P; Dewar JA; Albanell J; Limentani SA; Campone M; Chang JC; Patre M; Strasak A; de Haas SL; Xu J; Garcia-Saenz JA
    Ann Oncol; 2016 Jul; 27(7):1249-56. PubMed ID: 27052654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA.
    Swain SM; Im YH; Im SA; Chan V; Miles D; Knott A; Clark E; Ross G; Baselga J
    Oncologist; 2014 Jul; 19(7):693-701. PubMed ID: 24869931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer: A meta-analysis
.
    Tian T; Ye J; Zhou S
    Int J Clin Pharmacol Ther; 2017 Sep; 55(9):720-727. PubMed ID: 28737130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of docetaxel duration on clinical outcomes: exploratory analysis of CLEOPATRA, a phase III randomized controlled trial.
    Miles D; Im YH; Fung A; Yoo B; Knott A; Heeson S; Beattie MS; Swain SM
    Ann Oncol; 2017 Nov; 28(11):2761-2767. PubMed ID: 29112701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.
    Luen SJ; Salgado R; Fox S; Savas P; Eng-Wong J; Clark E; Kiermaier A; Swain SM; Baselga J; Michiels S; Loi S
    Lancet Oncol; 2017 Jan; 18(1):52-62. PubMed ID: 27964843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.